Barclays raised the firm’s price target on Qiagen (QGEN) to $55 from $53 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the “most under-owned space in healthcare” creates a “great setup” for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Goldman Sachs’ Significant Stake in QIAGEN Revealed by AFM Notification
- Qiagen N.V. Receives Notification of Significant Shareholding by Massachusetts Financial Services
- Goldman Sachs’ Voting Rights in QIAGEN Revealed by AFM
- Qiagen downgraded to Neutral from Buy at Citi
- Qiagen price target lowered to EUR 46 from EUR 50 at Berenberg